SLC5A2 and type 2 diabetes mellitus: Newer therapies including glucagon-like peptide (GLP-1) analogues and sodium glucose cotransporter-2 inhibitors (SGLT-2) have revolutionized the treatment of T2DM by achieving weight loss, improving insulin sensitivity, and improving cardiovascular and renal outcomes [78].